Tumors evade the immune system though a myriad of mechanisms. Using checkpoint
inhibitors to help reprime T cells to recognize tumor has had great success in malignancies …

Over the last decades, advances in the knowledge of immunology have led to the
identification of immune checkpoints, reinvigorating cancer immunotherapy. Although …

T cell infiltration of solid tumors is associated with favorable patient outcomes, yet the
mechanisms underlying variable immune responses between individuals are not well …

Purpose: PD-1 checkpoint blockade has revolutionized the field of cancer immunotherapy,
yet the frequency of responding patients is limited by inadequate T-cell priming secondary to …

B-RafV600E inhibitors have been suggested to promote tumor regression with the help of
host immunity, but this hypothesis has not been examined directly in detail. In this study, we …

Cancer therapies that generate T cell-based anti-cancer immune responses are critical for
clinical success and are favored over traditional therapies. One way to elicit T cell immune …

Despite recent clinical advances in immunotherapy, a fraction of cancer patients fails to
respond to these interventions. Evidence from preclinical mouse models as well as clinical …

Autoimmune diseases (AID) have emerged as prominent contributors to disability and
mortality worldwide, characterized by intricate pathogenic mechanisms involving genetic …

Recent insights into the molecular and cellular mechanisms underlying cancer development
have revealed the tumor microenvironment (TME) immune cells to functionally affect the …

The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer
immune responses that eradicate malignant cells while generating immunological memory …